283 related articles for article (PubMed ID: 30986263)
1. Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
Guenther E; Klein N; Zapf S; Weil S; Schlosser C; Rubinsky B; Stehling MK
PLoS One; 2019; 14(4):e0215093. PubMed ID: 30986263
[TBL] [Abstract][Full Text] [Related]
2. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control.
Ting F; Tran M; Böhm M; Siriwardana A; Van Leeuwen PJ; Haynes AM; Delprado W; Shnier R; Stricker PD
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):46-52. PubMed ID: 26458959
[TBL] [Abstract][Full Text] [Related]
3. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.
van Riel LAMJG; Geboers B; Kabaktepe E; Blazevski A; Reesink DJ; Stijns P; Stricker PD; Casanova J; Dominguez-Escrig JL; de Reijke TM; Scheltema MJ; Oddens JR
BJU Int; 2022 Nov; 130(5):611-618. PubMed ID: 35474600
[TBL] [Abstract][Full Text] [Related]
5. Focal irreversible electroporation as primary treatment for localized prostate cancer.
van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
[TBL] [Abstract][Full Text] [Related]
6. Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
Geboers B; Scheltema MJ; Blazevski A; Katelaris A; Doan P; Ali I; Agrawal S; Barreto D; Matthews J; Haynes AM; Delprado W; Shnier R; Thompson JE; Stricker PD
BJU Int; 2023 Jun; 131 Suppl 4():14-22. PubMed ID: 36594205
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
[TBL] [Abstract][Full Text] [Related]
9. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
[TBL] [Abstract][Full Text] [Related]
10. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.
Scheltema MJ; Chang JI; Böhm M; van den Bos W; Blazevski A; Gielchinsky I; Kalsbeek AMF; van Leeuwen PJ; Nguyen TV; de Reijke TM; Siriwardana AR; Thompson JE; de la Rosette JJ; Stricker PD
World J Urol; 2018 Sep; 36(9):1383-1389. PubMed ID: 29594551
[TBL] [Abstract][Full Text] [Related]
11. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes.
Blazevski A; Gondoputro W; Scheltema MJ; Amin A; Geboers B; Barreto D; Haynes AM; Shnier R; Delprado W; Agrawal S; Thompson JE; Stricker PD
BMC Urol; 2022 Mar; 22(1):28. PubMed ID: 35236338
[TBL] [Abstract][Full Text] [Related]
12. Irreversible Electroporation for the Ablation of Prostate Cancer.
Karagiannis A; Varkarakis J
Curr Urol Rep; 2019 Sep; 20(10):63. PubMed ID: 31478109
[TBL] [Abstract][Full Text] [Related]
13. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
[TBL] [Abstract][Full Text] [Related]
14. Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study.
Yaxley WJ; Gianduzzo T; Kua B; Oxford R; Yaxley JW
Investig Clin Urol; 2022 May; 63(3):285-293. PubMed ID: 35534217
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
van den Bos W; de Bruin DM; van Randen A; Engelbrecht MR; Postema AW; Muller BG; Varkarakis IM; Skolarikos A; Savci-Heijink CD; Jurhill RR; Zondervan PJ; Laguna Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
Eur Radiol; 2016 Jul; 26(7):2252-60. PubMed ID: 26449559
[TBL] [Abstract][Full Text] [Related]
17. Salvage irreversible electroporation for radio-recurrent prostate cancer - the prospective FIRE trial.
Blazevski A; Geboers B; Scheltema MJ; Gondoputro W; Doan P; Katelaris A; Agrawal S; Baretto D; Matthews J; Haynes AM; Delprado W; Shnier R; van den Bos W; Thompson JE; Lawrentschuk N; Stricker PD
BJU Int; 2023 Jun; 131 Suppl 4():23-31. PubMed ID: 36495482
[TBL] [Abstract][Full Text] [Related]
18. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer.
Scheltema MJ; Geboers B; Blazevski A; Doan P; Katelaris A; Agrawal S; Barreto D; Shnier R; Delprado W; Thompson JE; Stricker PD
BJU Int; 2023 Jun; 131 Suppl 4():6-13. PubMed ID: 36495481
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.
Beyer LP; Pregler B; Nießen C; Michalik K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
Clin Hemorheol Microcirc; 2016; 64(3):501-506. PubMed ID: 27935553
[TBL] [Abstract][Full Text] [Related]
20. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD
BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
